Kees van Grootheest

2.0k total citations
40 papers, 1.5k citations indexed

About

Kees van Grootheest is a scholar working on Toxicology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Kees van Grootheest has authored 40 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Toxicology, 12 papers in Pediatrics, Perinatology and Child Health and 10 papers in Pharmacology. Recurrent topics in Kees van Grootheest's work include Pharmacovigilance and Adverse Drug Reactions (30 papers), Drug-Induced Adverse Reactions (9 papers) and Pharmaceutical studies and practices (9 papers). Kees van Grootheest is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (30 papers), Drug-Induced Adverse Reactions (9 papers) and Pharmaceutical studies and practices (9 papers). Kees van Grootheest collaborates with scholars based in Netherlands, New Zealand and Switzerland. Kees van Grootheest's co-authors include Eugène van Puijenbroek, Florence van Hunsel, Lolkje de Jong‐van den Berg, Anneke Passier, Linda Härmark, Sten Olsson, Mary Couper, Lolkje T.W. de Jong‐van den Berg, C Hooft and Bruno H. Stricker and has published in prestigious journals such as Vaccine, British Journal of Clinical Pharmacology and Drug Safety.

In The Last Decade

Kees van Grootheest

38 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kees van Grootheest Netherlands 23 1.1k 487 418 326 303 40 1.5k
Florence van Hunsel Netherlands 23 995 0.9× 405 0.8× 405 1.0× 387 1.2× 346 1.1× 122 1.8k
Linda Härmark Netherlands 23 812 0.7× 325 0.7× 297 0.7× 286 0.9× 198 0.7× 59 1.4k
Keith Farrar United Kingdom 2 914 0.8× 659 1.4× 387 0.9× 340 1.0× 421 1.4× 3 2.3k
Thomas Walley United Kingdom 9 984 0.9× 711 1.5× 486 1.2× 365 1.1× 447 1.5× 26 2.6k
Ghada Miremont‐Salamé France 22 801 0.7× 279 0.6× 182 0.4× 331 1.0× 142 0.5× 76 1.8k
Françoise Haramburu France 30 1.5k 1.3× 483 1.0× 311 0.7× 605 1.9× 258 0.9× 129 2.7k
Harald Dormann Germany 21 585 0.5× 685 1.4× 243 0.6× 202 0.6× 192 0.6× 85 1.7k
Peter G. M. Mol Netherlands 25 450 0.4× 328 0.7× 443 1.1× 118 0.4× 178 0.6× 116 1.9k
Domenico Motola Italy 25 369 0.3× 198 0.4× 247 0.6× 424 1.3× 178 0.6× 87 1.7k
Emma Davies United Kingdom 13 440 0.4× 342 0.7× 132 0.3× 113 0.3× 99 0.3× 22 1.1k

Countries citing papers authored by Kees van Grootheest

Since Specialization
Citations

This map shows the geographic impact of Kees van Grootheest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kees van Grootheest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kees van Grootheest more than expected).

Fields of papers citing papers by Kees van Grootheest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kees van Grootheest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kees van Grootheest. The network helps show where Kees van Grootheest may publish in the future.

Co-authorship network of co-authors of Kees van Grootheest

This figure shows the co-authorship network connecting the top 25 collaborators of Kees van Grootheest. A scholar is included among the top collaborators of Kees van Grootheest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kees van Grootheest. Kees van Grootheest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrison‐Woolrych, Mira, Linda Härmark, Ming Tan, Simran Maggo, & Kees van Grootheest. (2012). Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres. European Journal of Clinical Pharmacology. 68(7). 1065–1072.
2.
Härmark, Linda, Eugène van Puijenbroek, & Kees van Grootheest. (2012). Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. European Journal of Clinical Pharmacology. 69(2). 209–215. 20 indexed citations
3.
Grootheest, Kees van, et al.. (2011). Effectiveness of Pharmacovigilance Training of General Practitioners. Drug Safety. 34(9). 755–762. 19 indexed citations
4.
Hunsel, Florence van, Linda Härmark, Shanthi Pal, Sten Olsson, & Kees van Grootheest. (2011). Experiences with Adverse Drug Reaction Reporting by Patients. Drug Safety. 35(1). 45–60. 113 indexed citations
5.
Härmark, Linda & Kees van Grootheest. (2011). Web-based intensive monitoring: from passive to active drug surveillance. Expert Opinion on Drug Safety. 11(1). 45–51. 27 indexed citations
6.
Hunsel, Florence van, et al.. (2010). Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. European Journal of Clinical Pharmacology. 66(11). 1143–1150. 65 indexed citations
7.
Puijenbroek, Eugène van, et al.. (2010). Fever Following Immunization with Influenza A (H1N1) Vaccine in Children. Drug Safety. 33(12). 1109–1115. 13 indexed citations
8.
Puijenbroek, Eugène van, et al.. (2010). Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. Drug Safety. 33(12). 1097–1108. 23 indexed citations
9.
Hunsel, Florence van, et al.. (2010). The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case–control study. Pharmacoepidemiology and Drug Safety. 20(3). 286–291. 45 indexed citations
10.
Hunsel, Florence van, Anneke Passier, & Kees van Grootheest. (2009). Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. British Journal of Clinical Pharmacology. 67(5). 558–564. 70 indexed citations
11.
Passier, Anneke, et al.. (2009). Reporting of Adverse Drug Reactions by General Practitioners. Drug Safety. 32(10). 851–858. 31 indexed citations
12.
Puijenbroek, Eugène van, et al.. (2007). Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiology and Drug Safety. 17(1). 76–81. 7 indexed citations
13.
Hooft, C, et al.. (2006). Adverse Drug Reaction-Related Hospitalisations. Drug Safety. 29(2). 161–168. 148 indexed citations
14.
Grootheest, Kees van, Eugène van Puijenbroek, & Lolkje T.W. de Jong‐van den Berg. (2004). Do pharmacists’ reports of adverse drug reactions reflect patients’ concerns?. Pharmacy World & Science. 26(3). 155–159. 18 indexed citations
15.
Grootheest, Kees van & Lolkje de Jong‐van den Berg. (2004). Patients’ role in reporting adverse drug reactions. Expert Opinion on Drug Safety. 3(4). 363–368. 55 indexed citations
16.
Grootheest, Kees van, et al.. (2003). Consumer Adverse Drug Reaction Reporting. Drug Safety. 26(4). 211–217. 88 indexed citations
17.
Grootheest, Kees van, Sten Olsson, Mary Couper, & Lolkje de Jong‐van den Berg. (2003). Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Safety. 13(7). 457–464. 138 indexed citations
18.
Grootheest, Kees van, et al.. (2003). Thromboembolism associated with the new contraceptive Yasmin. BMJ. 326(7383). 257–257. 22 indexed citations
19.
Puijenbroek, Eugène van, et al.. (2001). Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. British Journal of Clinical Pharmacology. 52(5). 579–586. 55 indexed citations
20.
MacKenzie, Marius, et al.. (2001). Neuropsychiatric symptoms during cefepime treatment.. Pharmacy World & Science. 23(1). 36–36. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence van Hunsel Breakdown of academic impact, for papers by Linda Härmark Breakdown of academic impact, for papers by Keith Farrar Breakdown of academic impact, for papers by Thomas Walley Breakdown of academic impact, for papers by Ghada Miremont‐Salamé Breakdown of academic impact, for papers by Françoise Haramburu Breakdown of academic impact, for papers by Harald Dormann Breakdown of academic impact, for papers by Peter G. M. Mol Breakdown of academic impact, for papers by Domenico Motola Breakdown of academic impact, for papers by Emma Davies
Rankless by CCL
2026